Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily S Brouwer

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Therapeutic Innovation & Regulatory Science|February 20, 2020
Masking in Pragmatic Trials: Who, What, and When to BlindJennifer B Christian, Emily S Brouwer, Cynthia J Girman, et al.
Epidemiology (Cambridge, Mass.)|April 10, 2014
Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patientsEmily S Brouwer, Sonia Napravnik, Joseph J Eron, et al.
Scientific Reports|July 30, 2021
Predictors of chronic opioid therapy in Medicaid beneficiaries with HIV who initiated antiretroviral therapyGYeon Oh, Emily S Brouwer, Erin L Abner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2021
Incidence of von Willebrand disease in Denmark, 1995-2016: A cohort studyAnne Sofie Dam Laursen, Thomas Bøjer Rasmussen, Gretchen R Chiu, et al.
Medical Care|April 23, 2013
Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical CohortEmily S Brouwer, Sonia Napravnik, Joseph J Eron, et al.
Pharmacoepidemiology and Drug Safety|January 18, 2012
Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health recordEmily S Brouwer, Suzanne L West, Marianne Kluckman, et al.
Pharmacoepidemiology and Drug Safety|February 27, 2013
Communicating quantitative risks and benefits in promotional prescription drug labeling or print advertisingSuzanne L West, Linda B Squiers, Lauren McCormack, et al.
Clinical Pharmacology and Therapeutics|May 8, 2018
Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)Hongbo Yuan, M Sanni Ali, Emily S Brouwer, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2013
Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney diseaseAndrew L Masica, Edward Ewen, Yahya A Daoud, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Therapeutic Innovation & Regulatory Science|February 20, 2020
Masking in Pragmatic Trials: Who, What, and When to BlindJennifer B Christian, Emily S Brouwer, Cynthia J Girman, et al.
Epidemiology (Cambridge, Mass.)|April 10, 2014
Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patientsEmily S Brouwer, Sonia Napravnik, Joseph J Eron, et al.
Scientific Reports|July 30, 2021
Predictors of chronic opioid therapy in Medicaid beneficiaries with HIV who initiated antiretroviral therapyGYeon Oh, Emily S Brouwer, Erin L Abner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2021
Incidence of von Willebrand disease in Denmark, 1995-2016: A cohort studyAnne Sofie Dam Laursen, Thomas Bøjer Rasmussen, Gretchen R Chiu, et al.
Medical Care|April 23, 2013
Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical CohortEmily S Brouwer, Sonia Napravnik, Joseph J Eron, et al.
Pharmacoepidemiology and Drug Safety|January 18, 2012
Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health recordEmily S Brouwer, Suzanne L West, Marianne Kluckman, et al.
Pharmacoepidemiology and Drug Safety|February 27, 2013
Communicating quantitative risks and benefits in promotional prescription drug labeling or print advertisingSuzanne L West, Linda B Squiers, Lauren McCormack, et al.
Clinical Pharmacology and Therapeutics|May 8, 2018
Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)Hongbo Yuan, M Sanni Ali, Emily S Brouwer, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2013
Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney diseaseAndrew L Masica, Edward Ewen, Yahya A Daoud, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
Pageof 3